Stonegate Investment Group LLC Has $224,000 Stock Holdings in Insulet Corporation $PODD

Stonegate Investment Group LLC trimmed its position in shares of Insulet Corporation (NASDAQ:PODD) by 96.3% during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 726 shares of the medical instruments supplier’s stock after selling 19,037 shares during the period. Stonegate Investment Group LLC’s holdings in Insulet were worth $224,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in PODD. Pier 88 Investment Partners LLC grew its holdings in shares of Insulet by 145.7% during the 3rd quarter. Pier 88 Investment Partners LLC now owns 6,610 shares of the medical instruments supplier’s stock worth $2,041,000 after purchasing an additional 3,920 shares in the last quarter. Vanguard Personalized Indexing Management LLC lifted its position in Insulet by 2.0% in the third quarter. Vanguard Personalized Indexing Management LLC now owns 15,969 shares of the medical instruments supplier’s stock worth $4,930,000 after purchasing an additional 316 shares during the period. LBP AM SA boosted its stake in Insulet by 1.6% during the third quarter. LBP AM SA now owns 15,878 shares of the medical instruments supplier’s stock worth $4,902,000 after buying an additional 249 shares in the last quarter. Mutual of America Capital Management LLC increased its holdings in Insulet by 1.8% in the 3rd quarter. Mutual of America Capital Management LLC now owns 9,236 shares of the medical instruments supplier’s stock valued at $2,851,000 after buying an additional 162 shares during the period. Finally, Whittier Trust Co. of Nevada Inc. raised its stake in shares of Insulet by 48.9% in the 3rd quarter. Whittier Trust Co. of Nevada Inc. now owns 131 shares of the medical instruments supplier’s stock valued at $40,000 after buying an additional 43 shares in the last quarter.

Insulet Stock Down 2.5%

NASDAQ PODD opened at $258.20 on Thursday. The stock’s 50 day simple moving average is $294.22 and its 200 day simple moving average is $309.62. Insulet Corporation has a one year low of $230.05 and a one year high of $354.88. The firm has a market cap of $18.16 billion, a PE ratio of 74.84, a price-to-earnings-growth ratio of 1.48 and a beta of 1.40. The company has a debt-to-equity ratio of 0.68, a current ratio of 2.87 and a quick ratio of 2.18.

Insulet (NASDAQ:PODD) last posted its quarterly earnings data on Thursday, November 6th. The medical instruments supplier reported $1.24 EPS for the quarter, topping analysts’ consensus estimates of $1.13 by $0.11. The company had revenue of $521.70 million for the quarter, compared to analyst estimates of $678.70 million. Insulet had a return on equity of 24.36% and a net margin of 9.76%.The business’s revenue was up 29.9% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.08 earnings per share. As a group, sell-side analysts forecast that Insulet Corporation will post 3.92 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on PODD shares. Truist Financial decreased their target price on shares of Insulet from $412.00 to $390.00 and set a “buy” rating on the stock in a research report on Thursday, December 18th. Canaccord Genuity Group lifted their price objective on Insulet from $432.00 to $450.00 and gave the company a “buy” rating in a report on Wednesday, December 17th. The Goldman Sachs Group reiterated a “buy” rating and issued a $365.00 price objective on shares of Insulet in a research note on Friday, January 9th. Evercore ISI initiated coverage on Insulet in a research report on Tuesday, December 16th. They set an “outperform” rating and a $370.00 target price for the company. Finally, Barclays upped their price target on Insulet from $300.00 to $301.00 and gave the company an “equal weight” rating in a research report on Wednesday, November 5th. Twenty equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $375.05.

Insulet Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.